| Literature DB >> 31393856 |
W Brian Dalton1, Eric Helmenstine1, Noel Walsh1, Lukasz P Gondek1, Dhanashree S Kelkar2, Abigail Read3, Rachael Natrajan3, Eric S Christenson1, Barbara Roman4, Samarjit Das4,5, Liang Zhao6, Robert D Leone6, Daniel Shinn1, Taylor Groginski1, Anil K Madugundu2,7,8, Arun Patil2,7, Daniel J Zabransky1, Arielle Medford1,9, Justin Lee1, Alex J Cole1, Marc Rosen1, Maya Thakar1, Alexander Ambinder1, Joshua Donaldson1, Amy E DeZern1, Karen Cravero1, David Chu1, Rafael Madero-Marroquin1,10, Akhilesh Pandey1,2,7,8,11, Paula J Hurley1,12, Josh Lauring1,13, Ben Ho Park1,14,15.
Abstract
Cancer-associated mutations in the spliceosome gene SF3B1 create a neomorphic protein that produces aberrant mRNA splicing in hundreds of genes, but the ensuing biologic and therapeutic consequences of this missplicing are not well understood. Here we have provided evidence that aberrant splicing by mutant SF3B1 altered the transcriptome, proteome, and metabolome of human cells, leading to missplicing-associated downregulation of metabolic genes, decreased mitochondrial respiration, and suppression of the serine synthesis pathway. We also found that mutant SF3B1 induces vulnerability to deprivation of the nonessential amino acid serine, which was mediated by missplicing-associated downregulation of the serine synthesis pathway enzyme PHGDH. This vulnerability was manifest both in vitro and in vivo, as dietary restriction of serine and glycine in mice was able to inhibit the growth of SF3B1MUT xenografts. These findings describe a role for SF3B1 mutations in altered energy metabolism, and they offer a new therapeutic strategy against SF3B1MUT cancers.Entities:
Keywords: Amino acid metabolism; Cancer; Metabolism; Oncology
Mesh:
Substances:
Year: 2019 PMID: 31393856 PMCID: PMC6819102 DOI: 10.1172/JCI125022
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808